Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:POLXF
CUSIPN/A
Phone416-755-2231
Debt
Debt-to-Equity Ratio0.05
Current Ratio4.27
Quick Ratio3.15
Price-To-Earnings
Trailing P/E Ratio8.75
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.28 million
Price / Sales0.67
Cash Flow$0.2067 per share
Price / Cash5.08
Book Value$1.70 per share
Price / Book0.62
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$440,000.00
Net Margins7.35%
Return on Equity7.31%
Return on Assets5.80%
Miscellaneous
EmployeesN/A
Outstanding Shares3,380,000
Market Cap$3.55 million
Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions
What is Polydex Pharmaceuticals' stock symbol?
Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."
How were Polydex Pharmaceuticals' earnings last quarter?
Polydex Pharmaceuticals Ltd (OTCMKTS:POLXF) posted its quarterly earnings data on Friday, June, 15th. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $1.48 million for the quarter. Polydex Pharmaceuticals had a net margin of 7.35% and a return on equity of 7.31%. View Polydex Pharmaceuticals' Earnings History.
When is Polydex Pharmaceuticals' next earnings date?
Who are some of Polydex Pharmaceuticals' key competitors?
Some companies that are related to Polydex Pharmaceuticals include Praxair (PX), Air Products & Chemicals (APD), JSR Corp/ADR (JSCPY), Kronos Worldwide (KRO), Minerals Technologies (MTX), Tronox (TROX), Valhi (VHI), Venator Materials (VNTR), Luxfer (LXFR), NL Industries (NL), LSB Industries (LXU) and Hydrogenics (HYGS).
Who are Polydex Pharmaceuticals' key executives?
Polydex Pharmaceuticals' management team includes the folowing people:
- Mr. George G. Usher, Chairman, CEO & Pres (Age 59)
- Mr. John Alfred Luce, CFO & Principal Accounting Officer (Age 71)
- Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 65)
Has Polydex Pharmaceuticals been receiving favorable news coverage?
News coverage about POLXF stock has trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Polydex Pharmaceuticals earned a media and rumor sentiment score of 0.03 on Accern's scale. They also gave news stories about the company an impact score of 46.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Polydex Pharmaceuticals.
How do I buy shares of Polydex Pharmaceuticals?
Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Polydex Pharmaceuticals' stock price today?
One share of POLXF stock can currently be purchased for approximately $1.05.
How big of a company is Polydex Pharmaceuticals?
Polydex Pharmaceuticals has a market capitalization of $3.55 million and generates $5.28 million in revenue each year.
How can I contact Polydex Pharmaceuticals?
Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231.
MarketBeat Community Rating for Polydex Pharmaceuticals (OTCMKTS POLXF)
MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
